▶ 調査レポート

世界の狂犬病ワクチン市場

• 英文タイトル:Rabies Vaccine Market - Growth, Trends, and Forecast (2019 - 2024)

Mordor Intelligenceが調査・発行した産業分析レポートです。世界の狂犬病ワクチン市場 / Rabies Vaccine Market - Growth, Trends, and Forecast (2019 - 2024) / C-MOR-100205資料のイメージです。• レポートコード:C-MOR-100205
• 出版社/出版日:Mordor Intelligence / 2019年9月
• レポート形態:英文、PDF、114ページ
• 納品方法:Eメール(受注後2-3営業日)
• 産業分類:医療
• 販売価格(消費税別)
  Single User¥629,000 (USD4,250)▷ お問い合わせ
  Multi User¥703,000 (USD4,750)▷ お問い合わせ
  Site License¥888,000 (USD6,000)▷ お問い合わせ
• ご注文方法:お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法:銀行振込(納品後、ご請求書送付)
レポート概要
本調査レポートでは、狂犬病ワクチンの世界市場について調査・分析し、狂犬病ワクチンの世界市場規模、市場動向、市場環境分析、市場展望、セグメント別分析、地域別分析、関連企業情報など以下の構成でお届け致します。

Market Overview
Rabies is a viral disease spread by the bite or scratch of an animal, however, the symptoms appear relatively slowly. In such cases, by the time, the symptoms appear, it is generally too late to save the patients. In the developed markets, the cases of human rabies is less because of more pet friendly communities and government initiatives, however, in emerging markets as well as low-income countries, there are fewer regulations to protect the people against animals bites and a large number of stray dogs can be observed across metropolitan cities as well as other cities and towns. Such factors raise the concerns regarding low protection against dog bites which raises the demand for rabies vaccines in such regions. However, limited resources, as well as negligence by government general public, are among the major causes which limit the use and adoption of rabies vaccines.

Scope of the Report

Domestic dogs are among the most common reservoir of viruses, which is regularly being checked by government initiatives adopted well across major cities and region in the world. However, still, several diagnostic tests and vaccines are given to prevent the cases of rabies across humans. The scope of the report covers the rabies vaccines market by product, vaccination type, end-user, and geography.

Key Market Trends

The Purified Chick Embryo Cell Rabies Vaccine is Estimated to Contribute Large, Over the Forecast Period

The purified chick embryo cell vaccine is used to protect people from post-exposure or pre-exposure. The veterinarians who are in contact with animals, such as cats, dogs, foxes, skunks, raccoons, bobcats, coyotes, and bats are more likely to be exposed to the rabies virus. Purified chick embryo cell rabies vaccines are prepared with the help of primary chick embryo cells derived from specific pathogen-free (SPF) eggs. It consists of purified and concentrated rabies virus antigen, inactivated with B-propiolactone. This vaccine acts by exposing a small dose of rabies virus to the patient in order to develop immunity to the disease. This vaccine can be used for post-exposure or pre-exposure. Such factors drive their importance and usage across hospitals and clinics.

North America is Estimated to Have Largest Share in the Global Market

According to the data published by Centers for Disease Control and Prevention (CDC) in the United States, wild animals accounted for 92.4% of the rabies cases, whereas domestic animals accounted for 48.7% cases of rabies in 2015. In the past few years, the number of human deaths attributed to rabies in the United States has declined due to two major reasons, the first one is animal control and vaccination programs. Secondly, effective human rabies vaccines and immunoglobulins have been developed over time. Similarly, major steps were taken across Canada and Mexico to protect the animals and humans rabies virus infection spread. A significant contribution by government and companies interests in this regions, makes this region, highly useful in terms of demand and use of rabies vaccines.

Competitive Landscape

The major market players are focusing on technological advancements and pet care initiatives in collabroation with hospitals and government channels. Some of the major players in the market are AstraZeneca (MedImmune), GlaxoSmithKline, Merck & Co Inc, Sanofi Pasteur, Inc, and Cadila Pharmaceuticals Ltd, among others.

Reasons to Purchase this report:
The market estimate (ME) sheet in Excel format
Report customization as per the client’s requirements
3 months of analyst support
Please note: This publisher does offer titles that are created upon receipt of order. If you are purchasing a PDF Email Delivery option above, the report will take approximately 2 business days to prepare and deliver.

レポート目次

1 INTRODUCTION
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study
2 RESEARCH METHODOLOGY
3 EXECUTIVE SUMMARY
4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Growing Burden of Mortality due to Rabies
4.2.2 Large Population of Stray Dogs in Low and Middle Income Countries
4.2.3 Growing Pet Management technological Advancements and Services
4.3 Market Restraints
4.3.1 Low Immunization Rates in Dogs
4.3.2 Lack of Awareness and Negligence by Government and Public
4.4 Porter’s Five Force Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5 MARKET SEGMENTATION
5.1 By Product Type
5.1.1 Baby Hamster Kidney (BHK)
5.1.2 Purified Chick Embryo Cell Rabies Vaccine
5.1.3 Vero Cell Rabies Vaccine
5.1.4 Other Product Types
5.2 By Vaccination Type
5.2.1 Pre-Exposure Vaccination (PEV)
5.2.2 Post-Exposure Prophylaxis (PEP)
5.3 By End User
5.3.1 Animals
5.3.2 Humans
5.4 Geography
5.4.1 North America
5.4.1.1 United States
5.4.1.2 Canada
5.4.1.3 Mexico
5.4.2 Europe
5.4.2.1 France
5.4.2.2 Germany
5.4.2.3 United Kingdom
5.4.2.4 Italy
5.4.2.5 Spain
5.4.2.6 Rest of Europe
5.4.3 Asia Pacific
5.4.3.1 China
5.4.3.2 Japan
5.4.3.3 India
5.4.3.4 Australia
5.4.3.5 South Korea
5.4.3.6 Rest of Asia-Pacific
5.4.4 Middle East and Africa
5.4.4.1 GCC
5.4.4.2 South Africa
5.4.4.3 Rest of Middle East and Africa
5.4.5 South America
5.4.5.1 Brazil
5.4.5.2 Argentina
5.4.5.3 Rest of South America
6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 AstraZeneca (MedImmune)
6.1.2 Berna Biotech Ltd
6.1.3 GlaxoSmithKline
6.1.4 Merck & Co Inc
6.1.5 Novartis AG
6.1.6 Pfizer Inc
6.1.7 Sanofi Pasteur, Inc
6.1.8 Zoetis Animal Healthcare
6.1.9 * List Not Exhaustive
7 MARKET OPPORTUNITIES AND FUTURE TRENDS